Operating Margin - IPCA Laboratories Ltd (NSE:IPCALAB)

Watchlist Manager

Watchlist

Price: 1 517 INR 0.61%

Market Cap: 384.9B INR

15.5%

Current

13%

Average

5.9%

Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin

15.5%

Operating Profit

14.5B

Revenue

93.6B

Operating Margin Across Competitors

Country		Company	Market Cap	Operating Margin
IN		IPCA Laboratories Ltd NSE:IPCALAB	384.9B INR	16%
US		Eli Lilly and Co NYSE:LLY	966.6B USD	44%
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	3%
US		Johnson & Johnson NYSE:JNJ	523.5B USD	27%
CH		Roche Holding AG SIX:ROG	276.2B CHF	34%
UK		AstraZeneca PLC LSE:AZN	220.3B GBP	24%
CH		Novartis AG SIX:NOVN	219.7B CHF	33%
US		Merck & Co Inc NYSE:MRK	273.4B USD	38%
DK		Novo Nordisk A/S CSE:NOVO B	1.6T DKK	42%
IE	E	Endo International PLC LSE:0Y5F	213.9B USD	11%
US		Pfizer Inc NYSE:PFE	144.7B USD	29%

IPCA Laboratories Ltd
Glance View

Market Cap

384.9B INR

Industry

Pharmaceuticals

In the bustling corridors of the global pharmaceutical industry, IPCA Laboratories Ltd. stands as a formidable presence, deeply rooted in its commitment to innovative healthcare solutions. Established with a mission to enhance patient well-being, IPCA has grown from a modest formulation company in India into a multinational endeavor, celebrated for its prowess in the realms of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. This vertically integrated company meticulously controls every element of its production chain, securing its position as a trusted supplier to some of the world's leading pharmaceutical giants. IPCA's robust portfolio includes a wide array of therapeutic segments, from antimalarials and analgesics to antihypertensives and nutraceuticals, showcasing its versatility and comprehensive grasp over diverse medical needs. What sets IPCA apart in the crowded pharmaceutical landscape is its strategic blend of cutting-edge research, efficient manufacturing practices, and a global distribution network. The company invests significantly in research and development, channeling innovation into its drug development processes to sustain its competitive edge. Enhanced production capabilities at its state-of-the-art facilities ensure that IPCA not only meets stringent international standards but also operates at optimal cost efficiency. This enables the company to leverage economies of scale, thereby maximizing profitability. By exporting to over 100 countries and employing a robust marketing strategy, IPCA ensures its products have a wide reach across developed and emerging markets. Thus, through its integrated approach to drug development and distribution, IPCA Laboratories continues to cultivate a steady stream of revenue while contributing substantially to global healthcare.

View IPCALAB Analysis

IPCALAB Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

	Johnson & Johnson NYSE:JNJ	219.57 USD 0.47%
	Berkshire Hathaway Inc NYSE:BRK.A	738 690.9 USD -0.64%
	Bank of America Corp NYSE:BAC	52.59 USD 0.21%
	Mastercard Inc NYSE:MA	542.65 USD -0.76%
	UnitedHealth Group Inc NYSE:UNH	338.96 USD 1.19%
	Exxon Mobil Corp NYSE:XOM	129.13 USD -0.82%

	Franklin Covey Co NYSE:FC	21.06 USD 5.72%
	Mohawk Industries Inc NYSE:MHK	123.68 USD 3.28%
	Ardmore Shipping Corp NYSE:ASC	11.85 USD -0.5%
	ASGN Inc NYSE:ASGN	50.02 USD 1.3%
	Skyworks Solutions Inc NASDAQ:SWKS	58.46 USD -2.34%
	Weatherford International PLC NASDAQ:WFRD	84.11 USD -2.99%

	Johnson & Johnson NYSE:JNJ	219.57 USD 0.47%
	Bank of America Corp NYSE:BAC	52.59 USD 0.21%
	Mastercard Inc NYSE:MA	542.65 USD -0.76%
	Salesforce Inc NYSE:CRM	233.53 USD -2.52%
	Abbvie Inc NYSE:ABBV	216.75 USD -2.32%
	Home Depot Inc NYSE:HD	379.16 USD 0.85%

	Monolithic Power Systems Inc NASDAQ:MPWR	1 009.54 USD 2.64%
	Applovin Corp NASDAQ:APP	606.99 USD -1.74%
	Apple Inc NASDAQ:AAPL	258.21 USD -0.67%
	NVIDIA Corp NASDAQ:NVDA	187.05 USD 2.13%
	Cal-Maine Foods Inc NASDAQ:CALM	77.12 USD 4.68%
	Pro Medicus Ltd ASX:PME	203.5 AUD -1.4%

IPCA Laboratories Ltd
NSE:IPCALAB